Citigroup’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-886,780
Closed -$16.1M 7325
2020
Q4
$16.1M Sell
886,780
-21,800
-2% -$382K 0.01% 1191
2020
Q3
$16.2M Sell
908,580
-67,200
-7% -$1.22M 0.01% 1025
2020
Q2
$17.5M Buy
975,780
+42,100
+5% +$756K 0.01% 908
2020
Q1
$14.2M Sell
933,680
-143,162
-13% -$2.59M 0.01% 936
2019
Q4
$21.2M Buy
1,076,842
+110,985
+11% +$2.12M 0.02% 939
2019
Q3
$16.6M Sell
965,857
-168,961
-15% -$2.92M 0.01% 1039
2019
Q2
$20.1M Sell
1,134,818
-168,859
-13% -$3.07M 0.02% 924
2019
Q1
$26.6M Buy
+1,303,677
New +$26.2M 0.03% 687

Other funds holding TAK

Citigroup's TAK Position: Q1 2026 in Review

Citigroup increased its Takeda Pharmaceutical (TAK) stake by 1,778% in Q1 2026, buying an estimated $5.95M and bringing the position to 358,174 shares worth $6.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Citigroup first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $113M in Q4 2018. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Citigroup held 358,174 shares of Takeda Pharmaceutical worth $6.63M as of Q1 2026.
  • Citigroup bought 339,104 Takeda Pharmaceutical shares in Q1 2026, an estimated $5.95M.
  • Takeda Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1749 holding.
  • Citigroup first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • Citigroup's Takeda Pharmaceutical position peaked at $113M in Q4 2018.
  • 358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.